Florida-based AzurRx BioPharma is bolstering the company’s gastrointestinal disease pipeline with the $229 million acquisition of First Wave Bio and its small molecule therapeutics for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.

The Bill & Melinda Gates Foundation will make a $35 million equity investment in privately owned Exscientia Ltd. to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Sept. 8.

BioSpace takes a look at some of the top stories from day one of the Annual Biomarkers for Alzheimer’s Disease Summit held August 25-26, 2021.

Bayer AG is buying Vividion Therapeutics, a San Diego-based company that focuses on drug development using protein surface screening, in a $2 billion deal.

Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.

Regeneron Pharmaceuticals Inc. and AstraZeneca today announced that the companies entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

The U.S. Food and Drug Administration approved Rezurock (belumosudil) as a new treatment option for anyone over 12 years of age with chronic graft-versus-host disease after two prior lines of therapy have failed. 

Hong Kong-based Insilico Medicine closed on a Series C financing round worth $255 million.

Florida-based Cantex Pharmaceuticals forged a licensing deal with vTv Therapeutics for a drug that had initially been developed as a potential treatment for Alzheimer’s disease. Cantex intends to repurpose the drug for multiple indications in cancer.

Novartis AG received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the Swiss drugmaker said on June 16.